

CITATION REPORT

List of articles citing

Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches

DOI: 10.1038/onc.2013.206
Oncogene, 2013, 32, 5501-11.

Source: <https://exaly.com/paper-pdf/55173876/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
578	Tenfibgen ligand nanoencapsulation delivers bi-functional anti-CK2 RNAi oligomer to key sites for prostate cancer targeting using human xenograft tumors in mice. 2014 , 9, e109970		15
577	The many faces of neuroendocrine differentiation in prostate cancer progression. 2014 , 4, 60		155
576	Curcumin Inhibits Prostate Cancer Bone Metastasis by Up-Regulating Bone Morphogenic Protein-7. 2014 , 5, 369-386		28
575	Natural compound Alternol induces oxidative stress-dependent apoptotic cell death preferentially in prostate cancer cells. 2014 , 13, 1526-36		19
574	SUV39H1/H3K9me3 attenuates sulforaphane-induced apoptotic signaling in PC3 prostate cancer cells. 2014 , 3, e131		23
573	The host microenvironment influences prostate cancer invasion, systemic spread, bone colonization, and osteoblastic metastasis. 2014 , 4, 364		39
572	WITHDRAWN: Novel anti-androgen receptor signaling agents: Understanding the mechanisms of resistance. 2014 ,		
571	Androgen receptor promotes the oncogenic function of overexpressed Jagged1 in prostate cancer by enhancing cyclin B1 expression via Akt phosphorylation. 2014 , 12, 830-42		29
570	Chromogranin A is a potential prognostic marker in prostate cancer patients treated with enzalutamide. 2014 , 74, 1691-6		44
569	MTA family of proteins in prostate cancer: biology, significance, and therapeutic opportunities. 2014 , 33, 929-42		19
568	Influence of AKT on progesterone action in endometrial diseases. 2014 , 91, 63		25
567	Targeting poly(ADP-ribose) polymerase and the c-Myb-regulated DNA damage response pathway in castration-resistant prostate cancer. 2014 , 7, ra47		59
566	Src signaling pathways in prostate cancer. 2014 , 33, 595-606		56
565	Is the detection rate of 18F-choline PET/CT influenced by androgen-deprivation therapy?. 2014 , 41, 1293-300	21	
564	Application of fluorine-containing non-steroidal anti-androgen compounds in treating prostate cancer. 2014 , 161, 1-10		7
563	Design and synthesis of N-acylated aza-goniothalamine derivatives and evaluation of their in vitro and in vivo antitumor activity. 2014 , 9, 2725-43		26
562	In vitro and in vivo characterisation of ASP9521: a novel, selective, orally bioavailable inhibitor of 17 β -hydroxysteroid dehydrogenase type 5 (17 β HSD5; AKR1C3). 2014 , 32, 860-70		35

561	Structure-based drug design of diphenyl aminoalkylphosphonates as prostate-specific antigen antagonists. 2014 , 54, 2967-79	4
560	Enzalutamide: looking back at its preclinical discovery. 2014 , 9, 837-45	6
559	Discovery of 1H-indole-2-carboxamides as novel inhibitors of the androgen receptor binding function 3 (BF3). 2014 , 57, 6867-72	47
558	Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model. 2014 , 184, 2163-73	43
557	Novel anti-androgen receptor signaling agents: Understanding the mechanisms of resistance. 2014 , 1, 30-39	
556	Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization. 2015 , 4, 3	83
555	Navigating Treatment of Metastatic Castration- Resistant Prostate Cancer: Nursing Perspectives. 2015 , 19, 723-32	6
554	The outcome and prognostic factors for lymph node recurrence after node-sparing definitive external beam radiotherapy for localized prostate cancer. 2015 , 13, 312	4
553	Early development of human lymphomas in a prostate cancer xenograft program using triple knock-out immunocompromised mice. 2015 , 75, 585-92	48
552	Development of enzalutamide for metastatic castration-resistant prostate cancer. 2015 , 1358, 13-27	8
551	RUNX1, an androgen- and EZH2-regulated gene, has differential roles in AR-dependent and -independent prostate cancer. 2015 , 6, 2263-76	54
550	Non-Coding RNAs in Castration-Resistant Prostate Cancer: Regulation of Androgen Receptor Signaling and Cancer Metabolism. 2015 , 16, 28943-78	24
549	Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression. 2015 , 10, e0117758	25
548	Potent anti-proliferative, pro-apoptotic activity of the <i>Maytenus royleanus</i> extract against prostate cancer cells: evidence in in-vitro and in-vivo models. 2015 , 10, e0119859	23
547	A profile of enzalutamide for the treatment of advanced castration resistant prostate cancer. 2015 , 7, 153-64	7
546	MicroRNA-34a regulates WNT/TCF7 signaling and inhibits bone metastasis in Ras-activated prostate cancer. 2015 , 6, 441-57	74
545	MYC Drives Pten/Trp53-Deficient Proliferation and Metastasis due to IL6 Secretion and AKT Suppression via PHLPP2. 2015 , 5, 636-51	52
544	The biology of castration-resistant prostate cancer. 2015 , 39, 17-28	18

543	IGFBP-2 - taking the lead in growth, metabolism and cancer. 2015 , 9, 125-42	48
542	Development of -Chromeno[3,4-]pyrido[3',2':4,5]thieno[2,3-e]pyridazin-6-ones as Par-4 Secretagogues. 2015 , 56, 3382-3384	6
541	The lncRNA DRAIC/PCAT29 Locus Constitutes a Tumor-Suppressive Nexus. 2015 , 13, 828-38	84
540	Transcription of Nrpd1 by the androgen receptor is regulated by nuclear filamin A in prostate cancer. 2015 , 22, 369-86	12
539	Differential effect of estradiol and bisphenol A on and expression in prostate cancer. 2015 , 2, 817-823	6
538	Co-targeting AR and HSP90 suppresses prostate cancer cell growth and prevents resistance mechanisms. 2015 , 22, 805-18	18
537	Simultaneous determination of multiple androgens in mice organs with liquid chromatography tandem mass spectrometry. 2015 , 115, 457-66	3
536	A randomised, double-blind study comparing the addition of bicalutamide with or without dutasteride to GnRH analogue therapy in men with non-metastatic castrate-resistant prostate cancer. 2015 , 51, 1555-69	12
535	Treatment of mCRPC in the AR-axis-targeted therapy-resistant state. 2015 , 26, 2044-56	69
534	Prognostic and Predictive Biomarkers for Castration Resistant Prostate Cancer. 2015 , 447-480	1
533	Proteomic Comparison and MRM-Based Comparative Analysis of Metabolites Reveal Metabolic Shift in Human Prostate Cancer Cell Lines. 2015 , 14, 3390-402	7
532	Ethanol extract of Remotiflori radix induces endoplasmic reticulum stress-mediated cell death through AMPK/mTOR signaling in human prostate cancer cells. 2015 , 5, 8394	11
531	Organ-Specific Cancer Metabolism and Its Potential for Therapy. 2016 , 233, 321-53	64
530	IGFBP-2: The dark horse in metabolism and cancer. 2015 , 26, 329-46	58
529	(18)F-Fluorocholine PET/CT for early response assessment in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. 2015 , 42, 1276-83	64
528	Glucose-regulated protein 78 mediates the anticancer efficacy of shikonin in hormone-refractory prostate cancer cells. 2015 , 36, 5063-70	10
527	Extracting the Benefit of Nexrutine for Cancer Prevention. 2015 , 1, 365-372	10
526	Androgen-regulation of the protein tyrosine phosphatase PTPRR activates ERK1/2 signalling in prostate cancer cells. 2015 , 15, 9	29

525	Improving clinical benefit for prostate cancer patients through the combination of androgen deprivation and immunotherapy. 2015 , 4, e1009303		5
524	Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone. 2015 , 112, 1717-24		105
523	Hepcidin regulation in prostate and its disruption in prostate cancer. 2015 , 75, 2254-63		97
522	Paradoxical and contradictory effects of imatinib in two cell line models of hormone-refractory prostate cancer. 2015 , 75, 923-35		18
521	Loss of STK11 expression is an early event in prostate carcinogenesis and predicts therapeutic response to targeted therapy against MAPK/p38. 2015 , 11, 2102-2113		16
520	TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression. <i>Nature Communications</i> , 2015 , 6, 8219	17.4	73
519	Molecular genetic mechanisms of drug resistance in prostate cancer. 2015 , 49, 638-648		6
518	GNL3 and SKA3 are novel prostate cancer metastasis susceptibility genes. 2015 , 32, 769-82		37
517	Androgen Deprivation Therapy and Secondary Hormone Therapy in the Management of Hormone-sensitive and Castration-resistant Prostate Cancer. 2015 , 86, 852-61		37
516	Androgen receptor and antiandrogen therapy in male breast cancer. 2015 , 368, 20-25		15
515	Endothelial Caveolin-1 regulates the radiation response of epithelial prostate tumors. 2015 , 4, e148		19
514	Integrated Proteomic and Glycoproteomic Analyses of Prostate Cancer Cells Reveal Glycoprotein Alteration in Protein Abundance and Glycosylation. 2015 , 14, 2753-63		92
513	AACR precision medicine series: Highlights of the integrating clinical genomics and cancer therapy meeting. 2015 , 782, 44-51		7
512	Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. 2015 , 67, 299-309		158
511	Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer. <i>Oncogene</i> , 2015 , 34, 4311-9	9.2	98
510	EGFR and IGF-1R in regulation of prostate cancer cell phenotype and polarity: opposing functions and modulation by T-cadherin. 2015 , 29, 494-507		13
509	DNA damage response and prostate cancer: defects, regulation and therapeutic implications. <i>Oncogene</i> , 2015 , 34, 2815-22	9.2	61
508	DNA Methylation Alterations as Biomarkers for Prostate Cancer. 2016 , 275-296		1

507	Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer. 2016 , 12, 409-26		25
506	Alterations of KRAS Exon 2 Codon 12/13 Mutation Status in Prostatic Adenocarcinoma; Bioinformatics Aspects. 2016 , 4,		1
505	Novel mechanism-based therapeutics for androgen axis blockade in castration-resistant prostate cancer. 2016 , 23, 279-90		10
504	Pilot study on the detection of antiandrogen resistance using serial diffusion-weighted imaging of bone metastases in prostate cancer. 2016 , 43, 1407-16		7
503	Neuroendocrine prostate cancer (NEPCa) increased the neighboring PCa chemoresistance via altering the PTHrP/p38/Hsp27/androgen receptor (AR)/p21 signals. <i>Oncogene</i> , 2016 , 35, 6065-6076	9.2	11
502	Influence of abiraterone acetate on circulating neuromediators in chemotherapy-naïve castration-resistant prostate cancer. 2016 , 76, 613-9		9
501	Dose-Dependent Therapeutic Distinction between Active and Passive Targeting Revealed Using Transferrin-Coated PGMA Nanoparticles. 2016 , 12, 351-9		44
500	Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes. 2016 , 16, 377		18
499	Cotargeting HSP90 and Its Client Proteins for Treatment of Prostate Cancer. 2016 , 15, 2107-18		16
498	KLF4 functions as an activator of the androgen receptor through reciprocal feedback. 2016 , 5, e282		17
497	International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries. 2016 , 1, e000040		25
496	ERK-mediated NF- κ B activation through ASIC1 in response to acidosis. 2016 , 5, e279		40
495	Immune Therapy for Prostate Cancer. 2016 , 22, 334-341		10
494	A triad of telomerase, androgen receptor and early growth response 1 in prostate cancer cells. 2016 , 17, 439-48		10
493	SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells. 2016 , 14, 574-85		29
492	Pathophysiology of Castration-Resistant Prostate Cancer. 2016 , 5-22		1
491	Geraniol suppresses prostate cancer growth through down-regulation of E2F8. 2016 , 5, 2899-2908		27
490	Defining the Influence of Germline Variation on Metastasis Using Systems Genetics Approaches. 2016 , 132, 73-109		2

489	Multivalent Peptoid Conjugates Which Overcome Enzalutamide Resistance in Prostate Cancer Cells. 2016 , 76, 5124-32	16
488	The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer. 2016 , 22, 5539-5552	48
487	Predictors of early androgen deprivation treatment failure in prostate cancer with bone metastases. 2016 , 5, 407-14	22
486	Predicting time to castration resistance in hormone sensitive prostate cancer by a personalization algorithm based on a mechanistic model integrating patient data. 2016 , 76, 48-57	18
485	Employing dynamical computational models for personalizing cancer immunotherapy. 2016 , 16, 1373-1385	19
484	Prescribing Patterns of Oral Antineoplastic Therapies Observed in the Treatment of Patients With Advanced Prostate Cancer Between 2012 and 2014: Results of an Oncology EMR Analysis. 2016 , 38, 1817-24	13
483	The androgen-induced protein AlbZIP facilitates proliferation of prostate cancer cells through downregulation of p21 expression. 2016 , 6, 37310	11
482	Personalized treatment of prostate cancer: better knowledge of the patient, the disease and the medicine. 2016 , 12, 2359-61	4
481	Heteronemin Is a Novel c-Met/STAT3 Inhibitor Against Advanced Prostate Cancer Cells. 2016 , 76, 1469-1483	28
480	Human Prostate Cancer Hallmarks Map. 2016 , 6, 30691	16
479	Advances in the management of castration resistant prostate cancer. 2016 , 355, i4405	50
478	PROTAC-induced BET protein degradation as a therapy for castration-resistant prostate cancer. 2016 , 113, 7124-9	427
477	The AR/NCOA1 axis regulates prostate cancer migration by involvement of PRKD1. 2016 , 23, 495-508	11
476	Glycosylation is an Androgen-Regulated Process Essential for Prostate Cancer Cell Viability. 2016 , 8, 103-116	46
475	EPI-001, A Compound Active against Castration-Resistant Prostate Cancer, Targets Transactivation Unit 5 of the Androgen Receptor. 2016 , 11, 2499-505	71
474	Cholesterol Sulfonation Enzyme, SULT2B1b, Modulates AR and Cell Growth Properties in Prostate Cancer. 2016 , 14, 776-86	21
473	Shp2 promotes metastasis of prostate cancer by attenuating the PAR3/PAR6/aPKC polarity protein complex and enhancing epithelial-to-mesenchymal transition. <i>Oncogene</i> , 2016 , 35, 1271-82	9.2 44
472	Biological activity of pyrazole and imidazole-dehydroepiandrosterone derivatives on the activity of 17 β -hydroxysteroid dehydrogenase. 2016 , 31, 53-62	4

471	The antipsychotic drug pimozide inhibits cell growth in prostate cancer through suppression of STAT3 activation. 2016 , 48, 322-8		42
470	N-cadherin promotes epithelial-mesenchymal transition and cancer stem cell-like traits via ErbB signaling in prostate cancer cells. 2016 , 48, 595-606		75
469	Peptide-Drug Conjugate GnRH-Sunitinib Targets Angiogenesis Selectively at the Site of Action to Inhibit Tumor Growth. 2016 , 76, 1181-92		22
468	Rat Prostate Tumor Cells Progress in the Bone Microenvironment to a Highly Aggressive Phenotype. 2016 , 18, 152-61		7
467	SRPK1 inhibition in prostate cancer: A novel anti-angiogenic treatment through modulation of VEGF alternative splicing. 2016 , 107, 276-281		18
466	Metabolic Control. 2016 ,		1
465	Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer. <i>Oncogene</i> , 2016 , 35, 4807-15	9.2	21
464	TM4SF3 and AR: A Nuclear Complex that Stabilizes Both Proteins. 2016 , 30, 13-25		5
463	The molecular and cellular origin of human prostate cancer. 2016 , 1863, 1238-60		56
462	Edelfosine Promotes Apoptosis in Androgen-Deprived Prostate Tumors by Increasing ATF3 and Inhibiting Androgen Receptor Activity. 2016 , 15, 1353-63		12
461	CUDC-101, a Novel Inhibitor of Full-Length Androgen Receptor (fAR) and Androgen Receptor Variant 7 (AR-V7) Activity: Mechanism of Action and In Vivo Efficacy. 2016 , 7, 196-210		14
460	Opportunities and challenges in combination gene cancer therapy. 2016 , 98, 35-40		48
459	Cotargeting Androgen Receptor Splice Variants and mTOR Signaling Pathway for the Treatment of Castration-Resistant Prostate Cancer. 2016 , 22, 2744-54		40
458	Par-4 secretion: stoichiometry of 3-arylquinoline binding to vimentin. 2016 , 14, 74-84		15
457	Addition of Docetaxel to Androgen Deprivation Therapy for Patients with Hormone-sensitive Metastatic Prostate Cancer: A Systematic Review and Meta-analysis. 2016 , 69, 563-573		82
456	Estrogen Exhibits a Biphasic Effect on Prostate Tumor Growth through the Estrogen Receptor EKL5 Pathway. 2016 , 36, 144-56		20
455	Notch signaling in the prostate: critical roles during development and in the hallmarks of prostate cancer biology. 2016 , 142, 531-47		19
454	Factors predicting progression to castrate-resistant prostate cancer in patients with advanced prostate cancer receiving long-term androgen-deprivation therapy. 2017 , 119, 74-81		13

453	Gemcitabine Based Peptide Conjugate with Improved Metabolic Properties and Dual Mode of Efficacy. 2017 , 14, 674-685	12
452	Assessment of Evidence-Based Standards in the Treatment of Advanced Prostate Cancer in a Community Practice. 2017 , 4, 218-224	
451	Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer. 2017 , 120, 226-232	21
450	Noncoding RNA for personalized prostate cancer treatment: utilizing the 'dark matters' of the genome. 2017 , 14, 159-169	
449	Prostate Cancer Metastasis. 2017 , 33-59	1
448	Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality. <i>Oncogene</i> , 2017 , 36, 3417-3427	47
447	Proteomics analyses of prostate cancer cells reveal cellular pathways associated with androgen resistance. 2017 , 17, 1600228	11
446	Marine-derived chromopeptide A, a novel class I HDAC inhibitor, suppresses human prostate cancer cell proliferation and migration. 2017 , 38, 551-560	13
445	TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer. 2017 , 20, 172-178	14
444	Mechanisms of Therapeutic Resistance in Prostate Cancer. 2017 , 19, 13	59
443	Integrating phosphoproteomics into the clinical management of prostate cancer. 2017 , 6, 9	6
442	Development of 17 β -hydroxysteroid dehydrogenase type 3 as a target in hormone-dependent prostate cancer therapy. 2017 , 121, 10-16	7
441	Glycosylation is a global target for androgen control in prostate cancer cells. 2017 , 24, R49-R64	26
440	Prostate cancer stem cells: from theory to practice. 2017 , 51, 95-106	12
439	Role of 20-Hydroxyeicosatetraenoic Acid (20-HETE) in Androgen-Mediated Cell Viability in Prostate Cancer Cells. 2017 , 8, 243-256	5
438	Exercise medicine for advanced prostate cancer. 2017 , 11, 247-257	33
437	Polyphenic trait promotes liver cancer in a model of epigenetic instability in mice. 2017 , 66, 235-251	9
436	Phosphorylation-induced conformational dynamics in an intrinsically disordered protein and potential role in phenotypic heterogeneity. 2017 , 114, E2644-E2653	55

435	Disrupting Androgen Receptor Signaling Induces Snail-Mediated Epithelial-Mesenchymal Plasticity in Prostate Cancer. 2017 , 77, 3101-3112		43
434	Improved survival for patients with de novo metastatic prostate cancer in the last 20 years. 2017 , 72, 20-27		30
433	A Constitutive Intrinsic Inflammatory Signaling Circuit Composed of miR-196b, Meis2, PPP3CC, and p65 Drives Prostate Cancer Castration Resistance. 2017 , 65, 154-167		39
432	Regulated expression of the TP α isoform of the human T prostanoid receptor by the tumour suppressors FOXP1 and NKX3.1: Implications for the role of thromboxane in prostate cancer. 2017 , 1863, 3153-3169		3
431	Loss of ABHD5 promotes the aggressiveness of prostate cancer cells. 2017 , 7, 13021		22
430	Extracellular vesicles released by mesenchymal-like prostate carcinoma cells modulate EMT state of recipient epithelial-like carcinoma cells through regulation of AR signaling. 2017 , 410, 100-111		24
429	WNT signalling in prostate cancer. 2017 , 14, 683-696		148
428	Multi-scale mechanical characterization of prostate cancer cell lines: Relevant biological markers to evaluate the cell metastatic potential. 2017 , 1861, 3109-3119		8
427	Non-Mono-Exponential Analysis of Diffusion-Weighted Imaging for Treatment Monitoring in Prostate Cancer Bone Metastases. 2017 , 7, 5809		7
426	Loss of SPDEF and gain of TGFBI activity after androgen deprivation therapy promote EMT and bone metastasis of prostate cancer. 2017 , 10,		36
425	Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer. 2017 , 77, 1373-1380		15
424	The Synthesis and Biological Characterization of Acetal-Free Mimics of the Tumor-Associated Carbohydrate Antigens. 2017 , 74, 137-237		4
423	Inhibition of the androgen receptor induces a novel tumor promoter, ZBTB46, for prostate cancer metastasis. <i>Oncogene</i> , 2017 , 36, 6213-6224	9.2	24
422	Prostate cancer immunotherapy: the path forward. 2017 , 11, 225-230		5
421	ING3 promotes prostate cancer growth by activating the androgen receptor. 2017 , 15, 103		21
420	Label retention and stem cell marker expression in the developing and adult prostate identifies basal and luminal epithelial stem cell subpopulations. 2017 , 8, 95		9
419	The role of salvage extended lymph node dissection in patients with rising PSA and PET/CT scan detected nodal recurrence of prostate cancer. 2017 , 20, 85-92		37
418	Stimulation of cellular senescent processes, including secretory phenotypes and anti-oxidant responses, after androgen deprivation therapy in human prostate cancer. 2017 , 165, 219-227		9

417	The role of GATA2 in lethal prostate cancer aggressiveness. 2017 , 14, 38-48		49
416	The optimal treatment of metastatic hormone-naive prostate cancer: abiraterone acetate or docetaxel?. 2017 , 13, 2785-2790		3
415	Development of cell-penetrating bispecific antibodies targeting the N-terminal domain of androgen receptor for prostate cancer therapy. 2017 , 30, 785-793		14
414	Epithelial-mesenchymal transition in prostate cancer: an overview. 2017 , 8, 35376-35389		105
413	Self-assembled albumin nanoparticles for combination therapy in prostate cancer. 2017 , 12, 7777-7787		32
412	Androgen Receptor-Dependent and -Independent Mechanisms Involved in Prostate Cancer Therapy Resistance. <i>Cancers</i> , 2017 , 9,	6.6	53
411	Prostate Cancer and Aspirin Use: Synopsis of the Proposed Molecular Mechanisms. 2017 , 8, 145		17
410	Targeting Apoptotic Activity Against Prostate Cancer Stem Cells. 2017 , 18,		16
409	Anticancer potential of novel curcumin analogs towards castrate-resistant prostate cancer. 2018 , 52, 579-588		9
408	Metformin: A Bridge between Diabetes and Prostate Cancer. 2017 , 7, 243		24
407	Prostate Cancer Stem Cell Markers Drive Progression, Therapeutic Resistance, and Bone Metastasis. 2017 , 2017, 8629234		57
406	Multi-drug loaded micelles delivering chemotherapy and targeted therapies directed against HSP90 and the PI3K/AKT/mTOR pathway in prostate cancer. 2017 , 12, e0174658		12
405	Treatment with the WNT5A-mimicking peptide Foxy-5 effectively reduces the metastatic spread of WNT5A-low prostate cancer cells in an orthotopic mouse model. 2017 , 12, e0184418		44
404	GABARAPL1 suppresses metastasis by counteracting PI3K/Akt pathway in prostate cancer. 2017 , 8, 4449-4459	11	
403	Therapeutic Approaches Targeting MYC-Driven Prostate Cancer. 2017 , 8,		55
402	Cancer/Testis Antigens: "Smart" Biomarkers for Diagnosis and Prognosis of Prostate and Other Cancers. 2017 , 18,		21
401	ANTITUMOR EFFECTS OF CHRYSANTHEMIN IN PC-3 HUMAN PROSTATE CANCER CELLS ARE MEDIATED VIA APOPTOSIS INDUCTION, CASPASE SIGNALLING PATHWAY AND LOSS OF MITOCHONDRIAL MEMBRANE POTENTIAL. 2017 , 14, 54-61		10
400	Induction of apoptosis and cell cycle arrest by ethyl acetate fraction of Phoenix dactylifera L. (Ajwa dates) in prostate cancer cells. 2018 , 218, 35-44		34

399	The Role of GPER Signaling in Carcinogenesis: A Focus on Prostate Cancer. 2018 , 59-117	3
398	[44Sc]Sc-PSMA-617 Biodistribution and Dosimetry in Patients With Metastatic Castration-Resistant Prostate Carcinoma. 2018 , 43, 323-330	18
397	Loss of scinderin decreased expression of epidermal growth factor receptor and promoted apoptosis of castration-resistant prostate cancer cells. 2018 , 8, 743-750	5
396	Texture analysis of apparent diffusion coefficient maps for treatment response assessment in prostate cancer bone metastases-A pilot study. 2018 , 101, 184-190	16
395	Targeting Galectin-1 Impairs Castration-Resistant Prostate Cancer Progression and Invasion. 2018 , 24, 4319-4331	20
394	Current and potential targets for drug design in the androgen receptor pathway for prostate cancer. 2018 , 13, 489-496	2
393	Long noncoding RNA MALAT1 enhances the docetaxel resistance of prostate cancer cells via miR-145-5p-mediated regulation of AKAP12. 2018 , 22, 3223-3237	62
392	Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. 2018 , 16, 643-654	24
391	Overexpression of $\alpha(1,6)$ fucosyltransferase in the development of castration-resistant prostate cancer cells. 2018 , 21, 137-146	20
390	Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models. 2018 , 142, 2163-2174	30
389	The retinamide VNLG-152 inhibits f-AR/AR-V7 and MNK-eIF4E signaling pathways to suppress EMT and castration-resistant prostate cancer xenograft growth. 2018 , 285, 1051-1063	26
388	The Genomics of Prostate Cancer: emerging understanding with technologic advances. 2018 , 31, S1-11	31
387	Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). 2018 , 78, 889-895	50
386	Frizzled-8 integrates Wnt-11 and transforming growth factor- β signaling in prostate cancer. <i>Nature Communications</i> , 2018 , 9, 1747	17.4 52
385	Inhibition of the Wnt/ β Catenin Pathway Overcomes Resistance to Enzalutamide in Castration-Resistant Prostate Cancer. 2018 , 78, 3147-3162	85
384	Expression of lncRNA MIR222HG co-transcribed from the miR-221/222 gene promoter facilitates the development of castration-resistant prostate cancer. 2018 , 7, 30	20
383	Capillarisin blocks prostate-specific antigen expression on activation of androgen receptor in prostate carcinoma cells. 2018 , 78, 242-249	7
382	Enhanced radiosensitization of enzalutamide via schedule dependent administration to androgen-sensitive prostate cancer cells. 2018 , 78, 64-75	28

381	The dark side of glucose transporters in prostate cancer: Are they a new feature to characterize carcinomas?. 2018 , 142, 2414-2424		38
380	Frequently rearranged and overexpressed Eatenin is responsible for low sensitivity of prostate cancer cells to androgen receptor and Eatenin antagonists. 2018 , 9, 24428-24442		2
379	Epigenetic and Pluripotency Aspects of Disseminated Cancer Cells During Minimal Residual Disease. 2018 , 1100, 1-18		1
378	Androgen Receptor Splice Variant 7 Drives the Growth of Castration Resistant Prostate Cancer without Being Involved in the Efficacy of Taxane Chemotherapy. <i>Journal of Clinical Medicine</i> , 2018 , 7,	5.1	12
377	Acquisition of resistance to androgen deprivation therapy in salivary duct carcinoma: A case report. 2018 , 10, 2036361318798867		1
376	Complete metabolic response of metastatic castration-resistant neuroendocrine carcinoma of the prostate after treatment with RRx-001 and reintroduced platinum doublets. 2018 , 6, 2478-2481		
375	PI3K pathway in prostate cancer: All resistant roads lead to PI3K. 2018 , 1870, 198-206		20
374	Clinical perspectives of PSMA PET/MRI for prostate cancer. 2018 , 73, e586s		9
373	Assessment of Treatment Response by 99mTc-MIP-1404 SPECT/CT: A Pilot Study in Patients With Metastatic Prostate Cancer. 2018 , 43, e250-e258		14
372	Identification of the Transcription Factor Relationships Associated with Androgen Deprivation Therapy Response and Metastatic Progression in Prostate Cancer. <i>Cancers</i> , 2018 , 10,	6.6	15
371	Castration-Resistant Prostate Cancer: Mechanisms, Targets and Treatment. 2018 , 1096, 117-133		24
370	A novel anti-proliferative pentapeptide (ILYMP) isolated from Cyclina'sinensis protein hydrolysate induces apoptosis of DU-145 prostate cancer cells. 2018 , 18, 771-778		6
369	The impact of transcription on metabolism in prostate and breast cancers. 2018 , 25, R435-R452		5
368	Concise Review: Prostate Cancer Stem Cells: Current Understanding. 2018 , 36, 1457-1474		55
367	Integrative (epi) Genomic Analysis to Predict Response to Androgen-Deprivation Therapy in Prostate Cancer. 2018 , 31, 110-121		10
366	IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. 2018 , 559, 363-369		163
365	High ANXA7 Potentiates Eucalyptol Toxicity in Hormone-refractory Prostate Cancer. 2018 , 38, 3831-3842		7
364	Androgen Receptor-CaMKK2 Axis in Prostate Cancer and Bone Microenvironment. 2018 , 9, 335		13

363	The Addition of Manganese Porphyrins during Radiation Inhibits Prostate Cancer Growth and Simultaneously Protects Normal Prostate Tissue from Radiation Damage. 2018 , 7,	21
362	Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer. 2018 , 174, 758-769.e9	234
361	Systematic Review and Network Meta-Analysis of Treatments for Chemotherapy-Naive Patients with Asymptomatic/Mildly Symptomatic Metastatic Castration-Resistant Prostate Cancer. 2018 , 21, 1259-1268 ¹¹	
360	Neue Therapieoptionen beim mCRPC. 2018 , 22, 32-38	
359	Prostate cancer in the era of "Omic" medicine: recognizing the importance of DNA damage repair pathways. 2018 , 6, 161	3
358	Mechanistic insights into the differential effects of thalidomide and lenalidomide in metastatic prostate cancer. 2018 , 14, 2383-2401	4
357	Identification of an oncogenic network with prognostic and therapeutic value in prostate cancer. 2018 , 14, e8202	17
356	Alternative splicing in prostate cancer. 2018 , 15, 663-675	87
355	High-Content Screening Campaign to Identify Compounds That Inhibit or Disrupt Androgen Receptor-Transcriptional Intermediary Factor 2 Protein-Protein Interactions for the Treatment of Prostate Cancer. 2018 , 16, 297-319	4
354	Overview of Genetically Engineered Mouse Models of Prostate Cancer and Their Applications in Drug Discovery. 2018 , 81, e39	6
353	Randomized Phase II Study Evaluating Akt Blockade with Ipatasertib, in Combination with Abiraterone, in Patients with Metastatic Prostate Cancer with and without PTEN Loss. 2019 , 25, 928-936	161
352	Cutaneous metastases from prostate cancer revealing neuroendocrine differentiation. 2019 , 46, 976-978	1
351	Inactivated FABP5 suppresses malignant progression of prostate cancer cells by inhibiting the activation of nuclear fatty acid receptor PPAR α . 2019 , 10, 80-96	11
350	Membrane-encapsulated camouflaged nanomedicines in drug delivery. 2019 , 14, 2067-2082	11
349	Molecular Underpinnings Governing Genetic Complexity of ETS-Fusion-Negative Prostate Cancer. 2019 , 25, 1024-1038	7
348	Differential expression of the TP α and TP β isoforms of the human T Prostanoid receptor during chronic inflammation of the prostate: Role for FOXP1 in the transcriptional regulation of TP α during monocyte-macrophage differentiation. 2019 , 110, 104277	1
347	Incidence of androgen receptor and androgen receptor variant 7 coexpression in prostate cancer. 2019 , 79, 1811-1822	3
346	Aromatase-induced endogenous estrogen promotes tumour metastasis through estrogen receptor- β /matrix metalloproteinase 12 axis activation in castration-resistant prostate cancer. 2019 , 467, 72-84	12

345	Revealing Metabolic Liabilities of Ralaniten To Enhance Novel Androgen Receptor Targeted Therapies. 2019 , 2, 453-467		14
344	Androgen receptor splicing variant 7: Beyond being a constitutively active variant. <i>Life Sciences</i> , 2019 , 234, 116768	6.8	8
343	Assays to Interrogate the Ability of Compounds to Inhibit the AF-2 or AF-1 Transactivation Domains of the Androgen Receptor. 2019 , 17, 364-386		1
342	Hypoxia induced cancer stem cell enrichment promotes resistance to androgen deprivation therapy in prostate cancer. 2019 , 152, 108497		18
341	Targeting Wnt/EZH2/microRNA-708 signaling pathway inhibits neuroendocrine differentiation in prostate cancer. 2019 , 5, 139		21
340	Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. 2019 , 30, 1813-1820		64
339	Activator of G protein signaling 3 modulates prostate tumor development and progression. 2019 , 40, 1504-1513		5
338	Targeting the SPOCK1-snail/slug axis-mediated epithelial-to-mesenchymal transition by apigenin contributes to repression of prostate cancer metastasis. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019 , 38, 246	12.8	33
337	LncRNA-p21 alters the antiandrogen enzalutamide-induced prostate cancer neuroendocrine differentiation via modulating the EZH2/STAT3 signaling. <i>Nature Communications</i> , 2019 , 10, 2571	17.4	82
336	Casticin inhibits human prostate cancer DU 145 cell migration and invasion via Ras/Akt/NF-B signaling pathways. 2019 , 43, e12902		62
335	BRD4 Regulates Metastatic Potential of Castration-Resistant Prostate Cancer through AHNK. 2019 , 17, 1627-1638		20
334	Androgen-responsive lncRNA LINC00304 promotes cell cycle and proliferation via regulating CCNA1. 2019 , 79, 994-1006		10
333	Deubiquitinase USP9X regulates the invasion of prostate cancer cells by regulating the ERK pathway and mitochondrial dynamics. 2019 , 41, 3292-3304		7
332	Nutlin3a-Loaded Nanoparticles Show Enhanced Apoptotic Activity on Prostate Cancer Cells. 2019 , 61, 489-497		4
331	Non-NAD-like PARP-1 inhibitors in prostate cancer treatment. 2019 , 167, 149-162		9
330	The synthetic retinoid ST1926 attenuates prostate cancer growth and potentially targets prostate cancer stem-like cells. 2019 , 58, 1208-1220		9
329	Renal Damaging Effect Elicited by Bicalutamide Therapy Uncovered Multiple Action Mechanisms As Evidenced by the Cell Model. 2019 , 9, 3392		7
328	Leukemia Inhibitory Factor Promotes Castration-resistant Prostate Cancer and Neuroendocrine Differentiation by Activated ZBTB46. 2019 , 25, 4128-4140		17

327	Functional and Mechanistic Interrogation of BET Bromodomain Degraders for the Treatment of Metastatic Castration-resistant Prostate Cancer. 2019 , 25, 4038-4048		16
326	Enzalutamide therapy for advanced prostate cancer: efficacy, resistance and beyond. 2018 , 26, R31-R52		22
325	DHX15 is up-regulated in castration-resistant prostate cancer and required for androgen receptor sensitivity to low DHT concentrations. 2019 , 79, 657-666		6
324	Targeting the TLK1/NEK1 DDR axis with Thioridazine suppresses outgrowth of androgen independent prostate tumors. 2019 , 145, 1055-1067		20
323	The long noncoding RNA HORAS5 mediates castration-resistant prostate cancer survival by activating the androgen receptor transcriptional program. <i>Molecular Oncology</i> , 2019 , 13, 1121-1136	7.9	21
322	Androgen deprivation therapy with chemotherapy or abiraterone for patients with metastatic hormone-naïve prostate cancer: a systematic review and meta-analysis. 2019 , 15, 1167-1179		4
321	Targeting androgen receptor-independent pathways in therapy-resistant prostate cancer. 2019 , 6, 91-98		4
320	Metabolomics Biomarkers of Prostate Cancer: A Systematic Review. 2019 , 9,		30
319	A Novel Small Molecule Inhibits Tumor Growth and Synergizes Effects of Enzalutamide on Prostate Cancer. 2019 , 371, 703-712		12
318	Tumor-infiltrating lymphocytes from human prostate tumors reveal anti-tumor reactivity and potential for adoptive cell therapy. 2019 , 8, e1672494		19
317	Analysis of Isoforms (and) as Selective Inhibitors of Androgen and TGF- β Signaling Reveals Distinct Biological and Prognostic Features in Prostate Cancer. <i>Cancers</i> , 2019 , 11,	6.6	4
316	Integrated analysis of miRNA landscape and cellular networking pathways in stage-specific prostate cancer. 2019 , 14, e0224071		10
315	Long Noncoding RNA from PVT1 Exon 9 Is Overexpressed in Prostate Cancer and Induces Malignant Transformation and Castration Resistance in Prostate Epithelial Cells. 2019 , 10,		10
314	Overexpression of SOCS3 mediated by adenovirus vector in mouse and human castration-resistant prostate cancer cells increases the sensitivity to NK cells in vitro and in vivo. 2019 , 26, 388-399		12
313	Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degradere of Androgen Receptor (AR) for the Treatment of Prostate Cancer. 2019 , 62, 941-964		157
312	Targeting Ezh2 could overcome docetaxel resistance in prostate cancer cells. 2019 , 19, 27		15
311	Passive-specific immunotherapy with monoclonal antibodies for prostate cancer: A systematic review. 2019 , 25, 903-917		4
310	SWATH proteomic profiling of prostate cancer cells identifies NUSAP1 as a potential molecular target for Galiellalactone. 2019 , 193, 217-229		12

309	Androgen deprivation-induced ZBTB46-PTGS1 signaling promotes neuroendocrine differentiation of prostate cancer. 2019 , 440-441, 35-46		16
308	The Genomics of Prostate Cancer: A Historic Perspective. 2019 , 9,		10
307	High Concentrations of Boric Acid Trigger Concentration-Dependent Oxidative Stress, Apoptotic Pathways and Morphological Alterations in DU-145 Human Prostate Cancer Cell Line. 2020 , 193, 400-409		16
306	Impact of the introduction of novel hormonal agents on metastatic castration-resistant prostate cancer treatment choice. 2020 , 26, 293-305		2
305	Current multifunctional albumin-based nanoplatfoms for cancer multi-mode therapy. 2020 , 15, 1-12		16
304	Disparities in prostate cancer incidence and mortality rates: Solvable or not?. 2020 , 80, 3-16		15
303	Cytoreductive treatment strategies for de novo metastatic prostate cancer. 2020 , 17, 168-182		19
302	The role of salvage lymph node dissection in nonmetastatic castration-resistant prostate cancer: A single center experience. 2020 , 38, 38.e9-38.e16		1
301	Attenuation of NAD[P]H:quinone oxidoreductase 1 aggravates prostate cancer and tumor cell plasticity through enhanced TGFβ signaling. 2020 , 3, 12		7
300	Androgen-induced expression of DRP1 regulates mitochondrial metabolic reprogramming in prostate cancer. 2020 , 471, 72-87		24
299	Systematic characterization of chromatin modifying enzymes identifies KDM3B as a critical regulator in castration resistant prostate cancer. <i>Oncogene</i> , 2020 , 39, 2187-2201	9.2	19
298	Epigenetic regulation of prostate cancer. 2020 , 7, 606-613		6
297	Development of an in vitro screening assay for PIP5K1β lipid kinase and identification of potent inhibitors. 2020 , 287, 3042-3064		2
296	Design and characterization of cereblon-mediated androgen receptor proteolysis-targeting chimeras. 2020 , 208, 112769		16
295	Crosstalk Between AR and Wnt Signaling Promotes Castration-Resistant Prostate Cancer Growth. 2020 , 13, 9257-9267		2
294	Rapamycin inhibits AR signaling pathway in prostate cancer by interacting with the FK1 domain of FKBP51. 2020 , 23, 100778		1
293	The Role of Cancer-Associated Fibroblasts in Prostate Cancer Tumorigenesis. <i>Cancers</i> , 2020 , 12,	6.6	20
292	Detection Rate of Ga-PSMA Ligand PET/CT in Patients with Recurrent Prostate Cancer and Androgen Deprivation Therapy. 2020 , 8,		4

291	Curcumin against Prostate Cancer: Current Evidence. 2020 , 10,	13
290	Epidermal Growth Factor Is Essential for the Maintenance of Novel Prostate Epithelial Cells Isolated From Patient-Derived Organoids. 2020 , 8, 571677	8
289	Unique targeting of androgen-dependent and -independent AR signaling in prostate cancer to overcome androgen resistance. 2020 , 34, 11511-11528	10
288	Curcumin Nanoparticles and Their Cytotoxicity in Docetaxel-Resistant Castration-Resistant Prostate Cancer Cells. 2020 , 8,	14
287	Downregulation of circular RNA hsa_circ_0000735 boosts prostate cancer sensitivity to docetaxel via sponging miR-7. 2020 , 20, 334	21
286	Sphere-derived Prostate Cancer Stem Cells Are Resistant to γ Cell Cytotoxicity. 2020 , 40, 5481-5487	3
285	Design, Synthesis and Cytotoxicity Evaluation of Novel Indole Derivatives Containing Benzoic Acid Group as Potential AKR1C3 Inhibitors. 2020 , 17, e2000519	2
284	Generation of Phenothiazine with Potent Anti-TLK1 Activity for Prostate Cancer Therapy. 2020 , 23, 101474	6
283	Targeting Oligometastasis with Stereotactic Ablative Radiation Therapy or Surgery in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review of Prospective Clinical Trials. 2020 , 3, 582-593	12
282	Roles of Interleukin-1 Receptor Antagonist in Prostate Cancer Progression. 2020 , 8,	3
281	Third-line Life-prolonging Drug Treatment in a Real-world Metastatic Castration-resistant Prostate Cancer Population: Results from the Dutch Castration-resistant Prostate Cancer Registry. 2021 , 7, 788-796	1
280	The management of patients with metastatic prostate cancer during the COVID-19 pandemic. 2020 , 16, 1455-1461	4
279	Oncogenic and tumor-suppressive microRNAs in prostate cancer. 2020 , 10, 50-59	2
278	PAWI-2: A novel inhibitor for eradication of cancer. 2020 , 29, 1147-1159	1
277	Through the Looking-Glass: Reevaluating DHEA Metabolism Through HSD3B1 Genetics. 2020 , 31, 680-690	6
276	Novel small-molecule LG1836 inhibits the in vivo growth of castration-resistant prostate cancer. 2020 , 80, 993-1005	2
275	Early upregulation of AR and steroidogenesis enzyme expression after 3 months of androgen-deprivation therapy. 2020 , 20, 71	2
274	Chemokine releasing particle implants for trapping circulating prostate cancer cells. 2020 , 10, 4433	3

273	Inhibition of the erythropoietin-producing receptor EPHB4 antagonizes androgen receptor overexpression and reduces enzalutamide resistance. 2020 , 295, 5470-5483		2
272	The JNK inhibitor AS602801 Synergizes with Enzalutamide to Kill Prostate Cancer Cells In Vitro and In Vivo and Inhibit Androgen Receptor Expression. 2020 , 13, 100751		8
271	TRA-1-60-positive/CD45 cells found in the peripheral blood of prostate cancer patients with metastatic disease - A proof-of-concept study. 2020 , 6, e03263		1
270	LncRNA promotes taxane resistance in castration-resistant prostate cancer via a BCL2A1-dependent mechanism. 2020 , 12, 1123-1138		7
269	Global Gene Expression Characterization of Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Patients. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	3
268	DNA Damage- But Not Enzalutamide-Induced Senescence in Prostate Cancer Promotes Senolytic Bcl-xL Inhibitor Sensitivity. 2020 , 9,		11
267	Cytokines and Chemokines as Mediators of Prostate Cancer Metastasis. 2020 , 21,		34
266	Moringa oleifera methanolic leaves extract induces apoptosis and G0/G1 cell cycle arrest via downregulation of Hedgehog Signaling Pathway in human prostate PC-3 cancer cells. 2020 , 44, e13338		10
265	A Comprehensive Analysis of FUT8 Overexpressing Prostate Cancer Cells Reveals the Role of EGFR in Castration Resistance. <i>Cancers</i> , 2020 , 12,	6.6	16
264	CTHRC1 affects malignant tumor cell behavior and is regulated by miR-30e-5p in human prostate cancer. 2020 , 525, 418-424		10
263	Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation. 2020 , 80, 367-375		4
262	Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer. <i>Nature Communications</i> , 2020 , 11, 384	17.4	37
261	Emerging role of glucocorticoid receptor in castration resistant prostate cancer: A potential therapeutic target. 2020 , 11, 696-701		6
260	AR-V7 Protein Expression in Circulating Tumour Cells Is Not Predictive of Treatment Response in mCRPC. 2020 , 104, 253-262		2
259	Tubulin-Binding 3,5-Bis(styryl)pyrazoles as Lead Compounds for the Treatment of Castration-Resistant Prostate Cancer. 2020 , 97, 409-422		3
258	Pharmacological and genetic targeting of 5-lipoxygenase interrupts c-Myc oncogenic signaling and kills enzalutamide-resistant prostate cancer cells via apoptosis. 2020 , 10, 6649		11
257	Metastatic castration-resistant prostate cancer: Academic insights and perspectives through bibliometric analysis. 2020 , 99, e19760		18
256	Flavonoids as Epigenetic Modulators for Prostate Cancer Prevention. 2020 , 12,		20

255	A novel GPCR target in correlation with androgen deprivation therapy for prostate cancer drug discovery. 2021 , 128, 195-203		0
254	Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors. 2021 , 28, 134-147.e14		13
253	A review of the effects and molecular mechanisms of dimethylcurcumin (ASC-J9) on androgen receptor-related diseases. 2021 , 97, 821-835		5
252	Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden. 2021 , 55, 1-8		3
251	Apalutamide and Overall Survival in Prostate Cancer. 2021 , 79, 150-158		66
250	Combination prostate cancer therapy: Prostate-specific membranes antigen targeted, pH-sensitive nanoparticles loaded with doxorubicin and tanshinone. 2021 , 28, 1132-1140		5
249	Androgen receptor splicing variant 7 (ARV7) inhibits docetaxel sensitivity by inactivating the spindle assembly checkpoint. 2021 , 296, 100276		1
248	Targeted inhibition of SIRT6 via engineered exosomes impairs tumorigenesis and metastasis in prostate cancer. 2021 , 11, 6526-6541		11
247	Vitamin D sufficiency enhances differentiation of patient-derived prostate epithelial organoids. 2021 , 24, 101974		5
246	Development of novel androgen receptor inhibitors to overcome castrate-resistant prostate cancer. 2021 , 23-46		
245	Body composition, physical function and quality of life in healthy men and across different stages of prostate cancer. 2021 , 24, 725-732		2
244	Targeting KDM4B that coactivates c-Myc-regulated metabolism to suppress tumor growth in castration-resistant prostate cancer. 2021 , 11, 7779-7796		5
243	Quantification and Optimization of Standard-of-Care Therapy to Delay the Emergence of Resistant Bone Metastatic Prostate Cancer. <i>Cancers</i> , 2021 , 13,	6.6	1
242	Macrophage-derived cholesterol contributes to therapeutic resistance in prostate cancer.		
241	Sensitizing the cytotoxic action of Docetaxel induced by Pentoxifylline in a PC3 prostate cancer cell line. 2021 , 21, 38		0
240	Hormone-Dependent Prostate Cancers are Dependent on Rac Signaling for Growth and Survival. 2021 , 20, 1052-1061		3
239	Phage display screening identifies a prostate specific antigen (PSA) prostate cancer cell specific peptide to retard castration resistance of prostate cancer. 2021 , 14, 101020		2
238	Novel Combinatorial Approaches to Tackle the Immunosuppressive Microenvironment of Prostate Cancer. <i>Cancers</i> , 2021 , 13,	6.6	5

237	Nanovectorization of Prostate Cancer Treatment Strategies: A New Approach to Improved Outcomes. 2021 , 13,		2
236	Comprehensive Analysis of Multiple Cohort Datasets Deciphers the Utility of Germline Single-Nucleotide Polymorphisms in Prostate Cancer Diagnosis. 2021 , 14, 741-752		0
235	Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer. 2021 , 216, 113307		9
234	Osteoblasts Generate Testosterone From DHEA and Activate Androgen Signaling in Prostate Cancer Cells. 2021 , 36, 1566-1579		0
233	Phosphorylation of the androgen receptor at Ser81 is co-sustained by CDK1 and CDK9 and leads to AR-mediated transactivation in prostate cancer. <i>Molecular Oncology</i> , 2021 , 15, 1901-1920	7.9	2
232	Lemur Tyrosine Kinases and Prostate Cancer: A Literature Review. 2021 , 22,		1
231	Effects of orlistat combined with enzalutamide and castration through inhibition of fatty acid synthase in a PC3 tumor-bearing mouse model. 2021 , 41,		1
230	Nuclear Export Inhibitor KPT-8602 Synergizes with PARP Inhibitors in Escalating Apoptosis in Castration Resistant Cancer Cells. 2021 , 22,		0
229	Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease. 2021 , 27, 4539-4548		2
228	Three-month early change in prostate-specific antigen levels as a predictive marker for overall survival during hormonal therapy for metastatic hormone-sensitive prostate cancer. 2021 , 14, 227		0
227	CircLRP6 contributes to prostate cancer growth and metastasis by binding to miR-330-5p to up-regulate NRBP1. 2021 , 19, 184		2
226	TRIMming Down Hormone-Driven Cancers: The Biological Impact of TRIM Proteins on Tumor Development, Progression and Prognostication. 2021 , 10,		3
225	Signalling transduction of O-GlcNAcylation and PI3K/AKT/mTOR-axis in prostate cancer. 2021 , 1867, 166129		3
224	Co-Adjuvant Therapy Efficacy of Catechin and Procyanidin B2 with Docetaxel on Hormone-Related Cancers In Vitro. 2021 , 22,		2
223	Macrophage-Derived Cholesterol Contributes to Therapeutic Resistance in Prostate Cancer. 2021 , 81, 5477-5490		8
222	Prognostic signatures associated with high infiltration of Tregs in bone metastatic prostate cancer. 2021 , 13, 17442-17461		2
221	DNA binding alters ARv7 dimer interactions. 2021 , 134,		1
220	Investigation of Anti-Tumor Effects of an MLK1 Inhibitor in Prostate and Pancreatic Cancers. 2021 , 10,		0

219	Contrasting genomic profiles from metastatic sites, primary tumors, and liquid biopsies of advanced prostate cancer. 2021 , 127, 4557-4564	0
218	Nucleoside antibiochemotherapy repressed the growth, chemoresistance, survival, and metastatic potentials of castration-resistant prostate cancer cells.	
217	Conformational dynamics of androgen receptors bound to agonists and antagonists. 2021 , 11, 15887	2
216	A Phase II, Randomized, Open-Label, Multi-arm Study of TAS-115 for Castration-Resistant Prostate Cancer Patients With Bone Metastases. 2021 ,	1
215	Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer. 2021 , 64, 12831-12854	14
214	KAT2A-mediated AR translocation into nucleus promotes abiraterone-resistance in castration-resistant prostate cancer. 2021 , 12, 787	2
213	Synthesis and biological evaluation of 3,5-diaryl-pyrazole derivatives as potential antiprostate cancer agents. 2021 , 354, e2100225	0
212	Androgen-deprivation induced senescence in prostate cancer cells is permissive for the development of castration-resistance but susceptible to senolytic therapy. 2021 , 193, 114765	4
211	Protein degradation technology: a strategic paradigm shift in drug discovery. 2021 , 14, 138	4
210	Designed, synthesized and biological evaluation of proteolysis targeting chimeras (PROTACs) as AR degraders for prostate cancer treatment. 2021 , 45, 116331	5
209	The application of theranostics in different stages of prostate cancer. 2021 , 17, 3637-3644	0
208	Targeting INMT and interrupting its methylation pathway for the treatment of castration resistant prostate cancer. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021 , 40, 307	12.8 2
207	Application of Organoid Models in Prostate Cancer Research. 2021 , 11, 736431	1
206	Identification of biomarkers, pathways and potential therapeutic target for docetaxel resistant prostate cancer. 2021 , 12, 2377-2388	3
205	Wnt/Beta-Catenin Signaling and Prostate Cancer Therapy Resistance. 2019 , 1210, 351-378	32
204	Divergent Modulation of Proteostasis in Prostate Cancer. 2020 , 1233, 117-151	4
203	lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5. 2017 , 25, 1959-1973	115
202	Castration-resistant prostate cancer: a strategy to enhance response to androgen deprivation. 2013 , 15, 709-10	2

201	Isorhamnetin inhibited the proliferation and metastasis of androgen-independent prostate cancer cells by targeting the mitochondrion-dependent intrinsic apoptotic and PI3K/Akt/mTOR pathway. 2020 , 40,	11
200	Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states.	3
199	Knockout of Akt1/2 suppresses the metastasis of human prostate cancer cells CWR22rv1 in vitro and in vivo. 2021 , 25, 1546-1553	5
198	Small molecule JQ1 promotes prostate cancer invasion via BET-independent inactivation of FOXA1. 2020 , 130, 1782-1792	15
197	The Adverse Effects of Androgen Deprivation Therapy in Prostate Cancer and the Benefits and Potential Anti-oncogenic Mechanisms of Progressive Resistance Training. 2020 , 6, 13	11
196	Contribution of Inherited DNA-Repair Gene Mutations to Hormone-Sensitive and Castrate-Resistant Metastatic Prostate Cancer and Implications for Clinical Outcome. 2019 , 3,	5
195	Androgen-dependent alternative mRNA isoform expression in prostate cancer cells. 2018 , 7, 1189	9
194	Potential Cross-Talk between Alternative and Classical NF- κ B Pathways in Prostate Cancer Tissues as Measured by a Multi-Staining Immunofluorescence Co-Localization Assay. 2015 , 10, e0131024	11
193	Up-Regulated Expression of LAMP2 and Autophagy Activity during Neuroendocrine Differentiation of Prostate Cancer LNCaP Cells. 2016 , 11, e0162977	30
192	MicroRNA and Transcription Factor Gene Regulatory Network Analysis Reveals Key Regulatory Elements Associated with Prostate Cancer Progression. 2016 , 11, e0168760	34
191	The PI3K regulatory subunit gene PIK3R1 is under direct control of androgens and repressed in prostate cancer cells. 2015 , 2, 755-64	19
190	MiR-4638-5p inhibits castration resistance of prostate cancer through repressing Kidins220 expression and PI3K/AKT pathway activity. 2016 , 7, 47444-47464	20
189	The activation of OR51E1 causes growth suppression of human prostate cancer cells. 2016 , 7, 48231-48249	37
188	Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide. 2016 , 7, 59781-59794	39
187	Dual targeting of androgen receptor and mTORC1 by salinomycin in prostate cancer. 2016 , 7, 62240-62254	21
186	Targeted suppression of AR-V7 using PIP5K1 β inhibitor overcomes enzalutamide resistance in prostate cancer cells. 2016 , 7, 63065-63081	28
185	Expression of the TP β and TP α isoforms of the thromboxane prostanoid receptor (TP) in prostate cancer: clinical significance and diagnostic potential. 2016 , 7, 73171-73187	6
184	MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling. 2017 , 8, 7964-7976	12

183	Implications of PI3K/AKT inhibition on REST protein stability and neuroendocrine phenotype acquisition in prostate cancer cells. 2017 , 8, 84863-84876	17
182	Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway. 2014 , 5, 9335-48	57
181	New targets for resistant prostate cancer. 2014 , 5, 8816-7	6
180	DNA damage induces GDNF secretion in the tumor microenvironment with paracrine effects promoting prostate cancer treatment resistance. 2015 , 6, 2134-47	30
179	Metformin-induced energy deficiency leads to the inhibition of lipogenesis in prostate cancer cells. 2015 , 6, 15652-61	42
178	Protein kinase C-related kinase 1 and 2 play an essential role in thromboxane-mediated neoplastic responses in prostate cancer. 2015 , 6, 26437-56	18
177	ACSL4 promotes prostate cancer growth, invasion and hormonal resistance. 2015 , 6, 44849-63	50
176	Galiellalactone induces cell cycle arrest and apoptosis through the ATM/ATR pathway in prostate cancer cells. 2016 , 7, 4490-506	28
175	Crosstalk between RON and androgen receptor signaling in the development of castration resistant prostate cancer. 2016 , 7, 14048-63	15
174	Primary versus castration-resistant prostate cancer: modeling through novel murine prostate cancer cell lines. 2016 , 7, 28961-75	11
173	Selection and characterization of DNA aptamer for metastatic prostate cancer recognition and tissue imaging. 2016 , 7, 36436-36446	35
172	MtDNA depleted PC3 cells exhibit Warburg effect and cancer stem cell features. 2016 , 7, 40297-40313	24
171	Androgen-induced miR-135a acts as a tumor suppressor through downregulating RBAK and MMP11, and mediates resistance to androgen deprivation therapy. 2016 , 7, 51284-51300	31
170	Role of epithelial mesenchymal transition in prostate tumorigenesis. 2015 , 21, 1240-8	34
169	Mediator kinase module and human tumorigenesis. 2015 , 50, 393-426	73
168	Advanced metastatic castration-resistant prostate cancer (mCRPC) treated with ARTA (androgen receptor targeted agents) and radium 223. 2017 , 11, 19-23	2
167	Long non-coding RNAs in prostate tumorigenesis and therapy (Review). 2020 , 13, 76	10
166	Androgen receptor and prostate cancer. 2016 , 3, 280-299	11

165	Prognostic role of chromogranin A in castration-resistant prostate cancer: A meta-analysis. 2018 , 20, 561-566	3
164	Biochemical recurrence after radical prostatectomy: Current status of its use as a treatment endpoint and early management strategies. 2019 , 35, 6-17	11
163	Efficacy of Androgen Deprivation Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Docetaxel-Based Chemotherapy. 2020 , 38, 226-235	3
162	Androgen-regulated transcription of drives alternative splicing patterns in prostate cancer. 2019 , 8,	25
161	Nomogram Incorporating Contrast-Enhanced Ultrasonography Predicting Time to the Development of Castration-Resistant Prostate Cancer. 2021 , 15, 11795549211049750	1
160	An RNA-Seq-Based Framework for Characterizing Canine Prostate Cancer and Prioritizing Clinically Relevant Biomarker Candidate Genes. 2021 , 22,	4
159	Long non-coding RNAs and their potential impact on diagnosis, prognosis, and therapy in prostate cancer: racial, ethnic, and geographical considerations. 2021 , 21, 1257-1271	2
158	Induction of Endoplasmic Reticulum Stress-Mediated Apoptosis by Aminosteroid RM-581 Efficiently Blocks the Growth of PC-3 Cancer Cells and Tumors Resistant or Not to Docetaxel. 2021 , 22,	1
157	Using predictive machine learning models for drug response simulation by calibrating patient-specific pathway signatures. 2021 , 7, 40	1
156	GLI3 Is Stabilized by SPOP Mutations and Promotes Castration Resistance via Functional Cooperation with Androgen Receptor in Prostate Cancer. 2021 ,	1
155	Personalized prostate cancer therapy based on systems analysis of the apoptosis regulatory network. 2015 , 17, 471-4	3
154	Prognostic and Predictive Biomarkers for Men With Castration-Resistant Prostate Cancer. 2014 , 1-27	
153	Transcriptional Regulation of the Human Thromboxane A2 Receptor Gene by Wilms's Tumour (WT). 163-187	
152	Modeling and Analysis of Hormone and Mitogenic Signal Integration in Prostate Cancer.	
151	Bone Metastases from Prostate Cancer: Hormonal Therapy. 2017 , 105-120	
150	Chapter 6 Plumbagin and Prostate Cancer Therapy. 2016 , 125-144	
149	Role of Chemohormonal Therapy in Management of Patients with Metastatic Hormone Sensitive Prostate Cancer. 2017 , 08, 1149-1159	
148	Current approaches to selection of the 1st line therapy in patients with metastatic hormone-sensitive prostate cancer. 2018 , 13, 85-90	1

- 147 Role of the androgen signaling axis in genitourinary malignancies. **2018**, 7, 1135-1142 1
- 146 Efficacy of Metformin in Treatment of Patients with Advanced Prostate Cancer: Single-arm Phase II Clinical Study. **2018**, 15, 23-28
- 145 Molecular Diagnostic in Prostate Cancer. **2019**, 187-198
- 144 Androgen deprivation upregulates SPINK1 expression and potentiates cellular plasticity in prostate cancer.
- 143 Androgen-regulated transcription of ESRP2 drives alternative splicing patterns in prostate cancer.
- 142 Enzalutamide-induced PTH1R-mediated TGFBR2 decrease in osteoblasts contributes to resistance in prostate cancer bone metastases. 0
- 141 Early upregulation of AR and steroidogenesis enzyme expression after 3 months of androgen-deprivation therapy..
- 140 Vitamin D Sufficiency Enhances Differentiation of Patient-Derived Prostate Epithelial Organoids.
- 139 Estado da arte no tratamento do c ncer de pr stata metast tico. 52-71
- 138 Targeting Inflammatory Signaling in Prostate Cancer Castration Resistance. *Journal of Clinical Medicine*, **2021**, 10, 5.1 0
- 137 Improving mathematical models of cancer by including resistance to therapy: a study in non-small cell lung cancer. 1
- 136 Using predictive machine learning models for drug response simulation by calibrating patient-specific pathway signatures.
- 135 Oxidative stress and redox signaling in CRPC progression: therapeutic potential of clinically-tested Nrf2-activators.. **2021**, 4, 96-124 3
- 134 Early upregulation of AR and steroidogenesis enzyme expressions after 3 months of androgen-deprivation therapy..
- 133 Establishment and characterization of prostate organoids from treatment-na ve patients with prostate cancer. **2022**, 23, 6 1
- 132 Androgen deprivation-induced OPHN1 amplification promotes castration-resistant prostate cancer. **2022**, 47, 1
- 131 Estimation of [177Lu]PSMA-617 tumor uptake based on voxel-wise 3D Monte Carlo tumor dosimetry in patients with metastasized castration resistant prostate cancer. **2020**, 59, 365-374
- 130 Current Challenges and Implications of Proteogenomic Approaches in Prostate Cancer. **2020**, 20, 1968-1980 0

129	TMEFF2 modulates the AKT and ERK signaling pathways. 2013 , 4, 83-94		11
128	Wnt signaling in castration-resistant prostate cancer: implications for therapy. <i>American Journal of Clinical and Experimental Urology</i> , 2014 , 2, 27-44	1.6	46
127	Tenfibgen-DMAT Nanocapsule Delivers CK2 Inhibitor DMAT to Prostate Cancer Xenograft Tumors Causing Inhibition of Cell Proliferation. 2014 , 6, 15-25		8
126	Long non-coding RNA UCA1 promotes cell progression by acting as a competing endogenous RNA of ATF2 in prostate cancer. 2017 , 9, 366-375		38
125	Androgen represses opioid growth factor receptor (OGFR) in human prostate cancer LNCaP cells and OGFR expression in human prostate cancer tissue. <i>American Journal of Clinical and Experimental Urology</i> , 2018 , 6, 164-171	1.6	5
124	Growth factors involve in cellular proliferation, differentiation and migration during prostate cancer metastasis. 2019 , 2, 1-13		1
123	Differential expression profiles of circRNAs in human prostate cancer based on chip and bioinformatic analysis. 2020 , 13, 1045-1052		4
122	Studies of hormonal regulation, phenotype plasticity, bone metastasis, and experimental therapeutics in androgen-repressed human prostate cancer (ARCaP) model. <i>American Journal of Clinical and Experimental Urology</i> , 2021 , 9, 277-286	1.6	
121	Imatinib mesylate inhibits androgen-independent PC-3 cell viability, proliferation, migration, and tumor growth by targeting platelet-derived growth factor receptor- α <i>Life Sciences</i> , 2021 , 288, 120171	6.8	1
120	Clinical and genomic features of SPOP-mutant prostate cancer. 2021 , 82, 260		3
119	Transcriptional regulation and ubiquitination-dependent regulation of HnRNPK oncogenic function in prostate tumorigenesis. 2021 , 21, 641		
118	Long Non-Coding RNA PCAT-NE1 Activates Autophagy via miR-6889-3p-Regulated VPS13A to Induce Neuroendocrine Differentiation. <i>SSRN Electronic Journal</i> ,	1	
117	A Systematic Review of Patients' Values, Preferences, and Expectations for the Treatment of Metastatic Prostate Cancer.. 2022 , 36, 9-18		0
116	Activation of TGF- β SMAD2 signaling by IL-6 drives neuroendocrine differentiation of prostate cancer through p38MAPK.. 2022 , 91, 110240		2
115	E2F transcription factor 2-activated DLEU2 contributes to prostate tumorigenesis by upregulating serum and glucocorticoid-induced protein kinase 1.. 2022 , 13, 77		1
114	Metabolic syndrome and its pharmacologic treatment are associated with the time to castration-resistant prostate cancer.. 2022 ,		0
113	Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell states.. <i>Nature Communications</i> , 2022 , 13, 141	17.4	7
112	Differential Gene Expression Profiles between N-Terminal Domain and Ligand-Binding Domain Inhibitors of Androgen Receptor Reveal Ralaniten Induction of Metallothionein by a Mechanism Dependent on MTF1.. <i>Cancers</i> , 2022 , 14,	6.6	0

111	Design, synthesis, and characterization of PROTACs targeting the androgen receptor in prostate and lung cancer models.. 2022 , e202100467		3
110	P2Y1 agonist HIC in combination with androgen receptor inhibitor abiraterone acetate impairs cell growth of prostate cancer.. <i>Apoptosis: an International Journal on Programmed Cell Death</i> , 2022 , 27, 283	5.4	0
109	Pre-Exposure to Stress-Inducing Agents Increase the Anticancer Efficacy of Focused Ultrasound against Aggressive Prostate Cancer Cells.. 2022 , 11,		0
108	A μ Value predictive of prostate cancer stemness, tumor immune landscape and immunotherapy response.. 2022 , 4, zcac010		0
107	Deciphering the Increased Prevalence of TP53 Mutations in Metastatic Prostate Cancer.. 2022 , 21, 11769351221087046		
106	Alpha Satellite RNA Levels Are Upregulated in the Blood of Patients with Metastatic Castration-Resistant Prostate Cancer.. 2022 , 13,		1
105	Overcoming Drug Resistance in Advanced Prostate Cancer by Drug Repurposing.. 2022 , 10,		4
104	Choosing Kinase Inhibitors for Androgen Deprivation Therapy-Resistant Prostate Cancer.. 2022 , 14,		0
103	The effects of exercise on body composition of prostate cancer patients receiving androgen deprivation therapy: An update systematic review and meta-analysis.. 2022 , 17, e0263918		1
102	High-dose-androgen-induced autophagic cell death to suppress the Enzalutamide-resistant prostate cancer growth via altering the circRNA-BCL2/miRNA-198/AMBRA1 signaling.. 2022 , 8, 128		1
101	Hematological Toxicity in Mice after High Activity Injections of Lu-PSMA-617.. 2022 , 14,		0
100	Targeting Oncoproteins for Degradation by Small Molecule-Based Proteolysis-Targeting Chimeras (PROTACs) in Sex Hormone-Dependent Cancers.. 2022 , 13, 839857		1
99	Overcoming prostate cancer drug resistance with a novel organosilicon small molecule. 2021 , 23, 1261-1274		0
98	High Keratin-7 Expression in Benign Peri-Tumoral Prostatic Glands Is Predictive of Bone Metastasis Onset and Prostate Cancer-Specific Mortality.. <i>Cancers</i> , 2022 , 14,	6.6	1
97	Novel forms of prostate cancer chemoresistance to successful androgen deprivation therapy demand new approaches: Rationale for targeting BET proteins.. 2022 ,		2
96	3JC48-3 (methyl 4'-methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1'-biphenyl]-3-carboxylate): a novel MYC/MAX dimerization inhibitor reduces prostate cancer growth.. 2022 ,		1
95	Image_1.TIF. 2020 ,		
94	Image_2.TIF. 2020 ,		

93 Image_3.TIF. 2020,

92 Image_4.TIF. 2020,

91 Image_5.TIF. 2020,

90 Table_1.DOCX. 2020,

89 Table_10.XLSX. 2020,

88 Table_11.XLSX. 2020,

87 Table_12.XLSX. 2020,

86 Table_13.XLSX. 2020,

85 Table_14.XLSX. 2020,

84 Table_2.DOCX. 2020,

83 Table_3.DOCX. 2020,

82 Table_4.XLSX. 2020,

81 Table_5.DOCX. 2020,

80 Table_6.DOCX. 2020,

79 Table_7.XLSX. 2020,

78 Table_8.XLSX. 2020,

77 Table_9.XLSX. 2020,

76 Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer.. *Medical Oncology*, 2022, 39, 63 3.7 1

75	Targeting CDCP1 gene transcription coactivated by BRD4 and CBP/p300 in castration-resistant prostate cancer.. <i>Oncogene</i> , 2022 ,	9.2	
74	Natural product myricetin is a pan-KDM4 inhibitor which with poly lactic-co-glycolic acid formulation effectively targets castration-resistant prostate cancer.. <i>Journal of Biomedical Science</i> , 2022 , 29, 29	13.3	1
73	PROTACs: Novel approach for cancer breakdown by breaking proteins.. <i>Life Sciences</i> , 2022 , 120577	6.8	0
72	Embryologic and hormonal contributors to prostate cancer in transgender women.. <i>American Journal of Clinical and Experimental Urology</i> , 2022 , 10, 63-72	1.6	
71	Src kinase: An attractive therapeutic target for prostate cancer. 2022 , 479-503		
70	Metronomic Chemotherapy in Prostate Cancer. <i>Journal of Clinical Medicine</i> , 2022 , 11, 2853	5.1	1
69	The Improved killing of both androgen-dependent and independent prostate cancer cells with etoposide loaded SPIONs coupled with NIR irradiation. <i>Biomaterials Science</i> ,	7.4	0
68	ELK1-Mediated YTHDF1 Drives Prostate Cancer Progression by Facilitating the Translation of Polo-Like Kinase 1 in an M6a Dependent Manner. <i>SSRN Electronic Journal</i> ,	1	
67	Anti-cancer function of microRNA -30e is mediated by negative regulation of HELLPAR , a noncoding macroRNA , and genes involved in ubiquitination and cell cycle progression in prostate cancer. <i>Molecular Oncology</i> ,	7.9	1
66	Circ_0004087 interaction with SND1 promotes docetaxel resistance in prostate cancer by boosting the mitosis error correction mechanism. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022 , 41,	12.8	0
65	Efficient aqueous remote loading of peptides in poly(lactic-co-glycolic acid). <i>Nature Communications</i> , 2022 , 13,	17.4	0
64	A Tale of Two Cancers: A Current Concise Overview of Breast and Prostate Cancer. <i>Cancers</i> , 2022 , 14, 2954	6.6	0
63	Targeting signaling pathways in prostate cancer: mechanisms and clinical trials. <i>Signal Transduction and Targeted Therapy</i> , 2022 , 7,	21	4
62	Role of microRNAs in regulation of WNT signaling pathway in urothelial and prostate cancers. <i>Egyptian Journal of Medical Human Genetics</i> , 2022 , 23,	2	
61	Relevance of Emerging Metabolomics-Based Biomarkers of Prostate Cancer: A Systematic Review. <i>Expert Reviews in Molecular Medicine</i> , 1-42	6.7	0
60	Nucleosome patterns in circulating tumor DNA reveal transcriptional regulation of advanced prostate cancer phenotypes.		
59	Differential Microbial Signature Associated With Benign Prostatic Hyperplasia and Prostate Cancer. <i>Frontiers in Cellular and Infection Microbiology</i> , 12,	5.9	2
58	Anticancer effect and apoptosis induction by azaflavanone derivative in human prostate cancer cells. <i>Apoptosis: an International Journal on Programmed Cell Death</i> ,	5.4	0

57	Nanotechnological Approaches in Prostate Cancer Therapy: Integration of engineering and biology. <i>Nano Today</i> , 2022 , 45, 101532	17.9	1
56	Implication of circulating microRNA-21 as a potential non-invasive diagnostic predictor of prostate cancer patients. 2022 , 34, 201081		
55	Challenges in Next Generation Sequencing of Homology Recombination Repair Genomic Variants in Prostate cancer: A Nationwide Survey and Calibration Project in China. <i>Prostate International</i> , 2022 ,	3-4	
54	The effects of boric acid and disodium pentaborate dehydrate in metastatic prostate cancer cells. <i>Journal of Radiology and Oncology</i> , 2022 , 6, 012-017	0	
53	Prostate cancer as a dedifferentiated organ: androgen receptor, cancer stem cells, and cancer stemness. <i>Essays in Biochemistry</i> ,	7.6	2
52	Androgen receptor signaling and spatial chromatin organization in castration-resistant prostate cancer. 9,		1
51	Molecular and pathological subtypes related to prostate cancer disparities and disease outcomes in African American and European American patients. 12,		0
50	Developing New Treatment Options for Castration-Resistant Prostate Cancer and Recurrent Disease. 2022 , 10, 1872		2
49	Androgen receptor splicing variant 7 (ARv7) promotes DNA damage response in prostate cancer cells. 2022 , 36,		0
48	FOXA1 inhibits hypoxia programs through transcriptional repression of HIF1A.		0
47	Reformation of the chondroitin sulfate glycoalyx enables progression of AR-independent prostate cancer. 2022 , 13,		1
46	Deciphering the enigmatic crosstalk between prostate cancer and Alzheimer's disease: A current update on molecular mechanisms and combination therapy. 2022 , 1868, 166524		
45	Differences in SUV39H1 and androgen receptor distribution in adenomyomatous hyperplasia and prostatic adenocarcinoma. 2022 , 25, 1387		0
44	Molecular Mechanism of Tanshinone against Prostate Cancer. 2022 , 27, 5594		0
43	Treatment Landscape for Patients with Castration-Resistant Prostate Cancer: Patient Selection and Unmet Clinical Needs. Volume 14, 339-350		1
42	Identification and development of a subtype-selective allosteric AKT inhibitor suitable for clinical development. 2022 , 12,		0
41	The endoplasmic reticulum stress response in prostate cancer.		0
40	Profile of chimeric RNAs and TMPRSS2-ERG e2e4 isoform in neuroendocrine prostate cancer. 2022 , 12,		1

39	Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses. 2022 , 27, e783-e795	0
38	A Phase II Study of sEphB4-HSA in Metastatic Castration-Resistant Prostate Cancer. 2022 ,	0
37	Identification of the Regulatory Targets of miR-3687 and miR-4417 in Prostate Cancer Cells Using a Proteomics Approach. 2022 , 23, 10565	0
36	Identification of castration-dependent and -independent driver genes and pathways in castration-resistant prostate cancer (CRPC). 2022 , 22,	0
35	Spatial Profiling of the Prostate Cancer Tumor Microenvironment Reveals Multiple Differences in Gene Expression and Correlation with Recurrence Risk. 2022 , 14, 4923	0
34	Nucleosome patterns in circulating tumor DNA reveal transcriptional regulation of advanced prostate cancer phenotypes.	2
33	Prognostic model for prostate cancer based on glycolysis-related genes and non-negative matrix factorization analysis. 2023 , 47, 339-350	0
32	Immunosuppressive environment in response to androgen deprivation treatment in prostate cancer. 13,	0
31	Acetyl-CoA Counteracts the Inhibitory Effect of Antiandrogens on Androgen Receptor Signaling in Prostate Cancer Cells. 2022 , 14, 5900	0
30	Distinct mechanisms mediating therapy-induced cellular senescence in prostate cancer. 2022 , 12,	0
29	Tumor-derived OBP2A promotes prostate cancer castration resistance. 2023 , 220,	0
28	SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?. 2022 , 22,	0
27	Antagonistic Functions of Androgen Receptor and NF- κ B in Prostate Cancer Experimental and Computational Analyses. 2022 , 14, 6164	1
26	Disruption of CCL2 in Mesenchymal Stem Cells as an Anti-Tumor Approach against Prostate Cancer. 2023 , 15, 441	0
25	Claudin-3 Loss of Expression Is a Prognostic Marker in Castration-Resistant Prostate Cancer. 2023 , 24, 803	0
24	The potential of using circulating tumour cells and their gene expression to predict docetaxel response in metastatic prostate cancer. 12,	1
23	Direct healthcare costs of non-metastatic castration-resistant prostate cancer in Italy. 2023 , 39,	0
22	Nano-Hydroxyapatite/PLGA Mixed Scaffolds as a Tool for Drug Development and to Study Metastatic Prostate Cancer in the Bone. 2023 , 15, 242	1

- 21 Targeting the N-terminal domain of the androgen receptor: The effective approach in therapy of CRPC. **2023**, 247, 115077
- 20 Latent representation of single-cell transcriptomes enables algebraic operations on cellular phenotypes.
- 19 An Overview of Epithelial-to-Mesenchymal Transition and Mesenchymal-to-Epithelial Transition in Canine Tumors: How Far Have We Come?. **2023**, 10, 19
- 18 The SMARCD Family of SWI/SNF Accessory Proteins Is Involved in the Transcriptional Regulation of Androgen Receptor-Driven Genes and Plays a Role in Various Essential Processes of Prostate Cancer. **2023**, 12, 124
- 17 Salvage stereotactic body radiation therapy for locally recurrent prostate cancer following primary radiation therapy, are benefits worth toxicity risks?: A systematic review.
- 16 Adverse Events and Androgen Receptor Signaling Inhibitors in the Treatment of Prostate Cancer: A Systematic Review and Multivariate Network Meta-analysis. **2023**,
- 15 Epigenetic mechanism of therapeutic resistance and potential of epigenetic therapeutics in chemorefractory prostate cancer. **2023**,
- 14 Cancer stem cell in prostate cancer progression, metastasis and therapy resistance. **2023**, 1878, 188887
- 13 An integrated in vitro/in silico approach to assess the anti-androgenic potency of isobavachin. **2023**, 176, 113764
- 12 Dissecting the effects of androgen deprivation therapy on cadherin switching in advanced prostate cancer: A molecular perspective. **2022**, 30, 137-155
- 11 Current status and clinical application of patient-derived tumor organoid model in kidney and prostate cancers. **2023**, 56, 24-31
- 10 Clinical applications of gonadotropin-releasing hormone analogues: a broad impact on reproductive medicine. **2023**,
- 9 LOX-1 Activation by oxLDL Induces AR and AR-V7 Expression via NF- κ B and STAT3 Signaling Pathways Reducing Enzalutamide Cytotoxic Effects. **2023**, 24, 5082
- 8 The Role of ER α and ER β in Castration-Resistant Prostate Cancer and Current Therapeutic Approaches. **2023**, 11, 826
- 7 Pseurotin A Validation as a Metastatic Castration-Resistant Prostate Cancer Recurrence-Suppressing Lead via PCSK9-LDLR Axis Modulation. **2023**, 21, 215
- 6 Molecular Similarities and Differences between Canine Prostate Cancer and Human Prostate Cancer Variants. **2023**, 11, 1100
- 5 Outcomes of Salvage Lymph Node Dissection for Prostate Cancer with Clinical Nodal Relapse: Results of a Multicentric, Retrospective Study. 108-115
- 4 MicroRNA-147b induces neuroendocrine differentiation of prostate cancer cells by targeting ribosomal protein RPS15A.

- 3 Ursolic Acid against Prostate and Urogenital Cancers: A Review of In Vitro and In Vivo Studies. **2023**
, 24, 7414
- 2 Cell-by-cell quantification of the androgen receptor in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progression.
- 1 LncRNA TYMSOS is a novel prognostic biomarker and associated with immune infiltration in prostate cancer.